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ABSTRACT 24 
Etifoxine (EFX) is a non-benzodiazepine psychoactive drug which exhibits anxiolytic effects through 25 
a dual mechanism, by directly binding to GABAA receptors (GABAARs) and to the mitochondrial 18-26 
kDa translocator protein, resulting in the potentiation of the GABAergic function. The b subunit 27 
subtype plays a key role in the EFX-GABAAR interaction, however this does not explain the anxiolytic 28 
effects of this drug. Here, we combined behavioral and electrophysiological experiments to challenge 29 
the role of the GABAAR a subunit in the EFX mode of action. After single administrations of 30 
anxiolytic doses (25-50 mg/kg, intraperitoneal), EFX did not induce any neurological nor locomotor 31 
impairments, unlike the benzodiazepine bromazepam (0.5-1 mg/kg, intraperitoneal). We established 32 
the EFX pharmacological profile on heteropentameric GABAARs constructed with α1 to α6 subunit 33 
expressed in Xenopus oocyte. Unlike what is known for benzodiazepines, neither the γ nor δ subunits 34 
influenced EFX-mediated potentiation of GABA-evoked currents. EFX acted first as a partial agonist 35 
on α2b3γ2S, α3b3γ2S, α6b3γ2S and α6b3d GABAARs, but not on α1b3γ2S, α4b3γ2S, α4b3d nor 36 
α5b3γ2S GABAARs. Moreover, EFX exhibited much higher positive allosteric modulation towards 37 
α2b3γ2S, α3b3γ2S and α6b3γ2S than for α1b3γ2S, α4b3γ2S and α5b3γ2S GABAARs. At 20 µM, 38 
corresponding to brain concentration at anxiolytic doses, EFX increased GABA potency to the highest 39 
extent for α3b3γ2S GABAARs. We built a docking model of EFX on α3β3γ2S GABAARs, which is 40 
consistent with a binding site located between α and β subunits in the extracellular domain. In 41 
conclusion, EFX preferentially potentiates α2b3γ2S and α3b3γ2S GABAARs, which might support 42 
its advantageous anxiolytic/sedative balance.  43 
 44 
Chemical compounds studied in this article: etifoxine (PubChem CID: 171544), bromazepam 45 
(PubChem CID: 2441), diazepam (PubChem CID: 3016) 46 
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 50 
Highlights 51 
• We investigated the influence of a subunits of GABAAR on the mode of action of etifoxine, 52 
a non-benzodiazepine compound. 53 
• Etifoxine induces anxiolysis without locomotion impairment and sedation in mice. 54 
• Etifoxine strongly potentiates α3b3γ2S and moderately α2b3γ2S and α6b3γ2S GABAARs 55 
compared to other GABAARs. 56 
• A docking model of EFX with α3b3γ2S GABAAR reveals a binding site at the α/b interface, 57 
close to the GABA-binding pocket. 58 
 59 
 60 
 61 
Abbreviations 62 
a(1-6)GABAARs, a1 to a6 subunit-containing GABAA receptors; BZD, benzodiazepine; BZP, 63 
bromazepam; DZP, diazepam; EFX, etifoxine; GABAAR, GABAA receptors; PAM, positive allosteric 64 
modulator; TEVC, two-electrode voltage-clamp 65 
66 
Page	4	of	37	
	
1. Introduction 67 
GABAARs are heteropentameric membrane proteins that belong to the cys-loop ligand-gated 68 
ion channel superfamily [1]. They are permeant to chloride ions in response to GABA and decrease 69 
neuronal excitability through membrane hyperpolarization. To date, 19 mammalian GABAAR 70 
subunits have been described and cloned (α1-6, β1-3, γ1-3, δ, ε, π, θ, ρ1-3) [1]. The putative 71 
combination of these subunits provides a large heterogeneity of GABAARs, with a stoichiometry of 72 
2α, 2β and a complementary subunit (mainly γ or δ). The contribution of GABAARs to fast or slow 73 
neuronal inhibition depends on their stoichiometry, their tissue distribution and their synaptic or 74 
extrasynaptic location. The most frequent assembly of synaptic receptors is α(1-3)β(1-3)γ(1-3), 75 
whereas extrasynaptic receptors dominantly contain α4 or α6 with β(1-3) and δ, or α5, β(1-3) and 76 
γ2 [1,2]. These differences in stoichiometry and distribution support their different 77 
neurophysiological functions and pharmacological properties [3,4]. 78 
GABAARs are targeted by benzodiazepines (BZDs) and other drugs for the treatment of 79 
anxiety, epilepsy and sleep disorders [5,6]. BZDs act as positive allosteric modulators (PAMs) of 80 
GABAARs by binding to a site at the interface between g2 subunit and α subunits [7]. Classical BZDs, 81 
such as diazepam (DZP, Fig. 1), bromazepam (BZP, Fig. 1) and lorazepam, exhibit similar 82 
pharmacological profile in behavioral tests [8,9] and display poor selectivity over GABAARs which 83 
contain α1, or α2 or α3 or α5 (α1GABAAR, α2GABAAR, α3GABAAR, or α5GABAAR) [10], which 84 
explains their undesirable effects, including withdrawal symptoms, sedation, amnesia, cognitive 85 
impairments and aggressiveness. Indeed, α1GABAARs are associated with sedation, BZD addiction, 86 
anterograde amnesia, anticonvulsant activity and cortical plasticity [10-12]. α2GABAARs and 87 
α3GABAARs have been linked to anxiolysis, antihyperalgesia and myorelaxation [13-15]. 88 
α5GABAARs are believed to be correlated to sedation, cognitive impairments and more recently, 89 
anxiolysis [14-17].  90 
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Etifoxine (2-ethylamino-6-chloro-4-methyl-4-phenyl-4H-3,1-benzoxazine hydrochloride, 91 
EFX, Fig. 1) is a non-BZD compound that exhibits anxiolytic and anticonvulsant effects in rodents 92 
[18] and is used for the treatment of anxiety-related disorders in humans [19,20]. EFX also displays 93 
anti-hyperalgesic and anti-inflammatory properties in different animal models [21,22]. Both in vitro 94 
and in vivo studies in rats suggested that the anxiolytic effects of EFX involve a dual mechanism of 95 
action, by directly binding to central GABAARs and to the mitochondrial 18-kDa translocator protein 96 
(TSPO) with, as a result, potentiation of the GABAergic function [23,24]. Indeed, it has been shown 97 
that EFX activates TSPO through a direct binding and consecutively stimulates the synthesis of 98 
neurosteroids, such as, allopregnanolone, which act as PAMs of GABAARs [25-27]. Although the 99 
affinity of EFX for GABAARs was twice higher than the one for TSPO (Ki of 6.1 µM vs Ki of 12.7 100 
µM), the predominance of one of the effect over the other, i.e. direct GABAARs binding or through 101 
TSPO activation, in mediating its anxiolytic effect, is still debated [25,28,29]. 102 
The importance of the β subunit in the mode of action of EFX on GABAARs has been clearly 103 
evidenced [24]. Constitutively-open homopentameric βGABAARs are inhibited by EFX. In addition, 104 
α1GABAARs and α2GABAARs embedding β2 or β3 are more sensitive to EFX than α1GABAARs and 105 
α2GABAARs with β1. These data underline the importance of the β subunit in the EFX-GABAAR 106 
interaction and for EFX-potentiation of GABA-induced currents of heteromeric GABAARs. However, 107 
homopentameric β2GABAARs are less sensitive to EFX than homopentameric β1GABAARs [24], 108 
suggesting that the nature of the α subunit might also play a role in EFX-GABAARs interaction. In 109 
addition, at anxiolytic doses, EFX has no sedative effects nor locomotion impairment in humans [19] 110 
or rodents [30] and this could hardly be explained by the equal potency of EFX on α2GABAAR and 111 
α1GABAAR since the latter is associated with sedation [10,12]. Thus, we hypothesized that the 112 
pharmacological profile of EFX reflects different sensitivities of all α subtypes containing-GABAARs. 113 
In this study, we first compared EFX and BZP in anxiolysis, sedation and locomotor 114 
impairment behavioral tests in acute conditions, in mice. The pharmacological effects of both EFX 115 
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and BZP already appear after a single administration [8,9,29,30]. Here, we determined the anxiolytic 116 
doses of EFX and their possible influences on motor performance and arousal. We then assessed the 117 
impact of α subunit isoforms on the effects of EFX on GABA-evoked currents. We characterized the 118 
pharmacological profile of EFX on murine synaptic GABAARs (α1b3γ2S, α2b3γ2S, α3b3γ2S, 119 
α4b3γ2S and α6b3γ2S) and extrasynaptic GABAARs (α5β3γ2S, α4β3δ and α6β3δ) using 120 
electrophysiology. This pharmacological study was completed with a 3D model, showing the 121 
interaction between EFX and GABAARs. Our results demonstrate that the EFX mode of action 122 
involves both α and β, but not γ or δ, subunits.  123 
  124 
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2. Materials and methods 125 
2.1 Ethical statements 126 
All animal procedures were carried out in accordance with the European Community council 127 
directive 2010/63/EU for the care and use of laboratory animals and were approved by our respective 128 
local ethical committees (N°CEEA.45 and N°CEEA.72 for mice and N°CEEA.2012.68 for Xenopus, 129 
https://www.ceea-paysdelaloire.com/) in addition to the French Ministry of Agriculture 130 
(authorization N°B49071 and N° 02200.02). The NC3R's ARRIVE guidelines were followed in the 131 
conduct and reporting of all experiments using animals. 132 
2.2 Animal care and conditioning 133 
Experiments were carried out using 7- to 9-week-old Balb/cByJ mice (25-30 g) purchased 134 
from Charles River Laboratory (Les Oncins, France). Ten mice per translucent polypropylene cage 135 
(internal dimensions in mm: 375 x 375 x 180, L x W x H) were housed under standard laboratory 136 
conditions (22 ± 2° C, 12-h light/dark cycle, lights on at 7:00 AM) with food (AO4, SAFE, France) 137 
and tap water available ad libitum. No less than one week of rest followed their arrival. Mice were 138 
habituated to the testing room at least 60 min before performing any behavioral evaluation. All tests 139 
occurred between 9:00 AM and 3:00 PM. The behavioral tests were performed by two well-trained 140 
experimenters, who remained unaware of the administered treatment. In addition, all equipment was 141 
wiped with 70% ethanol between animals to erase the olfactory stimuli. All experiments were 142 
performed in a randomized manner. Single administrations of EFX (12.5-150 mg/kg, expressed as 143 
hydrochloride salt) or BZP (0.25-1 mg/kg) were given by the intraperitoneal (IP) route, 30 min before 144 
each test, except in the stress-induced hyperthermia test in which the compounds were administered 145 
60 min before the test. Studies have shown that both compounds have a similar profile with plasma 146 
peak at 15-30 min [25,31-33]. The control animals received an equivalent volume of vehicle (0.9% 147 
NaCl, 1% tween 80 (v/v)). One male C57Bl/6N mouse was used for the cloning experiments. This 148 
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mouse had been included in a control group (not treated) from a previous protocol in which mice 149 
were purchased from Janvier Labs (Le Genest-Saint-Isle, France). Euthanasia was performed using 150 
CO2 (3 ml/min, 4 min). Adult female Xenopus laevis were purchased from CRB (Rennes, France) and 151 
had been bred in the laboratory in strict accordance with the recommendations of the Guide for the 152 
Care and Use of Laboratory Animals of the European Community. Oocytes were harvested from 153 
mature female Xenopus laevis frogs under 0.15% tricaine anaesthesia. All animals recovered after 2-154 
3 h. Every female is operated every three months, not less. A single female was used no more than 5 155 
times.  156 
2. 3 Compounds 157 
EFX hydrochloride (batch 653, Biocodex, France), and BZP (batch 5788, Francochim, 158 
France) (Fig. 1) were suspended in vehicle and administered (IP) in a volume of 10 ml/kg of body 159 
weight. For electrophysiology, EFX and DZP (batch 105F0451, Sigma, France) were dissolved in 160 
dimethylsulfoxide (DMSO) resulting in a maximal concentration of 0.1% DMSO, for oocyte 161 
perfusion (control experiments were performed to demonstrate no effect of DMSO). All other 162 
reagents and solvents were obtained from Sigma-Aldrich Merck (Saint-Louis, MO, USA) or Thermo 163 
Fisher Scientific (Waltham, Massachusetts, USA). 164 
 165 
 166 
 167 
 168 
 169 
 170 
Fig. 1. Structure of the positive allosteric modulators of GABAARs used in this study. The 2D structure of EFX (PubChem 171 
CID: 171544), DZP (PubChem CID: 3016) and BZP (PubChem CID: 2441) are illustrated. 172 
 173 
Etifoxine (EFX) Diazepam (DZP) Bromazepam (BZP)
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2.4 Anxiety-related behavioral assessment 174 
Stress-induced hyperthermia (SIH) is defined as the increase in body temperature observed 175 
when a subject is exposed to an external stressor [34]. The day preceding the experiment, the animals 176 
were isolated in smaller cages (dimensions: 265x160x140 mm). The body temperature (± 0.1°C) of 177 
one singly housed mouse was measured twice via a rectal probe (YSI n°423; 2 mm diameter) coupled 178 
to a thermometer (Letica-Temp812 model-Italia) at an interval of 10 min. The rectal temperature 179 
measurement procedure (handling, insertion of the probe) constitutes the stressor. Drugs were injected 180 
60 min before the first measurement (T1), followed by a second temperature measurement 10 min 181 
later (T2). Methodological experiments have shown that the optimal conditions for drug testing are 182 
found with an injection-test interval of 60 min or longer to avoid residual effects of the injection 183 
procedure. Indeed, using a 60 min-injection-stress interval results in a hyperthermic response 184 
comparable to animals that are not injected [35,36]. The reduction of SIH (∆T = T2-T1) is considered 185 
to reflect an anxiolytic-like effect [34-36]. Defensive burying after novel object exploration is a 186 
behavior that can be elicited in rodents in response to aversive or new stimuli [37]. Mice were singly 187 
housed in smaller cages (see above) with a sawdust depth of 2.5 cm the day before the test. Each 188 
mouse was confronted with an unfamiliar object (4x4x6 cm; aluminium) introduced in the centre of 189 
the cage. The time of contact or exploring the object (snout pointing toward the object at a distance 190 
< 1 cm with or without burying) was recorded for 10 min. The object was cleaned with alcohol (10%) 191 
between each trial. This behavioral approach reveals an anxiety-like or fear state and its suppression 192 
is associated with a reduction of the anxiety-like behavior [37]. 193 
2.5 Spontaneous locomotor activity 194 
Testing was conducted in a quiet room under a light level of approximately 400 lux. The motor 195 
activity cages (dimensions: 265x160x140 mm) were made of clear plastic and were changed between 196 
each animal; these cages contained a minimum amount of sawdust. The locomotor activity was 197 
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measured by infra-red beam interruptions that were counted by a control unit (OptaVarimex, 198 
Columbus, Ohio, USA). The sensitivity of this unit was set so that walking (horizontal activity) and 199 
rearing (vertical activity) were measured. The beam breaks corresponding to spontaneous locomotor 200 
activity were measured for 15 min. 201 
2.6 Rotarod performance  202 
The rotarod test assesses motor performance by measuring the capacity of mice to remain on 203 
a 3-cm-diameter rod revolving 16 rpm (model 7600; Ugo Basile, Comerio, Italy). The mice were 204 
trained to walk on the rotarod until they could complete three consecutive 120 s sessions without 205 
falling off the rod. Twenty-four hours later, selected animals were treated with drugs before being 206 
challenged. The rotarod performance time was measured three times, up to 120 s, and the mean was 207 
adopted as the performance time for each animal. 208 
2.7 GABAAR subunit cDNA expression vectors 209 
pRK7 plasmids containing cDNAs encoding rat α2 subunits were a kind gift from Professor 210 
Harmut Lüddens (University of Mainz, Mainz, Germany). The GABAAR α2 subunits from rat and 211 
mouse are identical in amino acid sequence. pGW1 (=pRK5) plasmids containing cDNAs encoding 212 
mouse β3 and γ2S subunits were kindly provided by Professor Steven J. Moss (Tufts University, 213 
Boston, USA). The cDNAs encoding the α3, α4, α5, α6 and d subunits used in this work were cloned 214 
in mouse brain as described below. 215 
2.8 RNA extraction, RT-PCR and cloning of full-length cDNAs encoding α3-6 and d subunits 216 
The brain was dissected from a male C57Bl/6N mouse for RNA extraction and purification. 217 
Total RNA was then extracted using TRIzol® Reagent (Ozyme/Biogentex, France). First strand 218 
cDNAs were synthesised from 5 µg of total RNA using SuperScriptTM III First-Strand Synthesis 219 
System Super Mix (Invitrogen, USA) in the presence of oligo (dT)20, according to the manufacturer’s 220 
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instructions. cDNAs encoding α3-6 and d subunits were amplified using gene-specific primer pairs 221 
encompassing each ORF (Supplemental Table 1) and high-fidelity thermostable DNA polymerase 222 
(Advantage 2 Proofreading Polymerase kit, Clontech, Saint-Germain-en-Laye, France). cDNAs 223 
fragments were purified with the Nucleospin PCR Cleanup Kit (Macherey-Nagel, Hoerdt, Germany) 224 
and were subsequently cloned into PCR® 4 TOPO® (Invitrogen). Each clone was sequenced twice 225 
on both strands using universal sense and reverse primers by GATC Biotech (Konstanz, Germany). 226 
Sequence analyses were performed using BioEdit sequence analysis software. To transfer α3-6 and d 227 
subunits ORFs into the pRK5 expression vector, we adapted the ligase-free method for directional 228 
cloning [38]. Plasmids and cDNA inserts were separately prepared by PCR using the proof reading 229 
polymerase, KOD DNA polymerase (Merck Millipore, Fontenay sous Bois, France). To generate 230 
sticky-end cDNAs, two individual PCR reactions were performed, PCR1 and PCR2, with gene-231 
specific primers containing short overhangs that allow annealing with the complementary overhangs 232 
of the plasmid. pRK5 plasmid was modified to clone the GABAAR subunit ORFs flanked at their 5’ 233 
end by alfalfa mosaic virus (AMV) coat protein (RNA 4) and at their 3’end by 3ʹ -untranslated 234 
regions (UTRs) from the Xenopus β-globin gene (3UTRXBG). The combination of both UTRs has 235 
been shown to improve expression in both oocytes and mammalian cells [39]. First, a fusion of AMV 236 
and 3’UTRXBG was constructed and cloned into pRK5 between EcoRI and XbaI. The resulting 237 
modified vector (pRK5-5AMV-3UTRXBG) was used as a template for two individual PCRs with the 238 
following pair primers: 5’-TAAACCAGCCTCAAGAACACCCGA-3’ with 5’ 239 
GGTGGAAGTATTTGAAAGAAAATTAAAAATA-3’ (PCR1), and 5’-240 
AAGCTTGATCTGGTTACCACTAAACC-3’ with 5’-241 
AAAATTAAAAATAAAAACGAATTCAATCGATA-3’ (PCR2). PCR1 and PCR2 products were 242 
purified and mixed in T4 ligase buffer. To generate cDNA with sticky ends, the amplicons were 243 
subjected to melting and reannealing, as previously described [38]. Inserts containing GABAAR 244 
subunit ORFs were also prepared in two individual PCRs (LIC-PCR1 and 2) with gene-specific 245 
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primer pairs (see Table S1 in supplementary data). Sticky-end inserts were obtained as described for 246 
the plasmid preparations. For each construct, sticky-ends plasmid and GABAA cDNA preparation 247 
were assembled in T4 ligase buffer and incubated for 2 h at 22°C. One to two microliters of this 248 
assemblage were used to transform chemically competent E. coli cells (DG1, Eurogentec, Seraing, 249 
Belgium). The resulting clones were sequenced as described above.  250 
2.9 Expression of GABAARs in Xenopus oocytes 251 
Adult female Xenopus laevis (CRB, Rennes, France) were anaesthetized in ice-cold water 252 
with 0.15% Tricaine (3-aminobenzoic acid ethyl ester, Sigma). Ovarian lobes were collected and 253 
washed in standard oocyte saline (SOS containing 100 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM 254 
MgCl2, 5 mM HEPES, pH 7.4). Stage V-VI oocytes were partially defolliculated by enzymatic 255 
treatment with 2 mg/ml collagenase (type IA, Sigma) in Ca2+-free SOS for 60 min. To express 256 
functional GABAAR, cDNA mixtures were directly injected into the nucleus (animal pole) of 257 
individual defolliculated oocytes in different volumes of DNA solution at a concentration of 50 ng/µl 258 
using a nanoinjector (Drummond Nanoject) (see Table S2 for receptor stoichiometry and DNA 259 
quantity injected). Following injection, the oocytes were kept at 18°C in SOS supplemented with 260 
gentamycin (50 μg/ml), penicillin (100 UI/ml), streptomycin (100 μg/ml), and sodium pyruvate 261 
(2.5 mM). The incubation medium was replaced every two days. Oocytes were incubated 1 to 2 days 262 
after DNA injection, depending on the GABAAR subtype.  263 
2.10 Electrophysiological recordings 264 
Injected oocytes were tested for GABAAR expression, at a holding potential of -60 mV using 265 
a two-electrode voltage clamp amplifier (TEV-200, Dagan Corporation, Minneapolis, USA). Digidata 266 
1440A interface (Axon CNS Molecular Devices, California, USA) and pCLAMP 10 software (Axon 267 
CNS Molecular Devices) were used for acquisition. Cells were continuously superfused with standard 268 
oocyte saline (SOS) at room temperature and were challenged with drugs in SOS. Electrodes were 269 
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filled with 1 M KCl / 2 M K acetate and had typical resistances of 0.5–2 MΩ in SOS. Drugs were 270 
perfused at a flow rate close to ~4 ml/min. EFX and DZP were applied for 2 min before co-application 271 
of GABA at EC10, (determined for each GABAAR subtype, see Table S2 in supplementary data) until 272 
the current response peaked. EFX was tested at concentrations ranging from 2 to 100 μM, 273 
corresponding to its clinical use. Between the two applications, the oocytes were washed in SOS for 274 
10-15 min to ensure full recovery from receptor desensitization (see Fig. 4A inbox). To control 275 
whether GABA-evoked currents were mediated by ternary α1-6β3γ2SGABAARs, control 276 
experiments were performed using SOS containing 10 µM Zn2+ to inhibit binary GABAARs [40]. Data 277 
were analysed using pCLAMP 10 software. Data are expressed as the mean ± SEM of 6-10 oocytes 278 
generated from at least two collections. Concentration-effect relationships were analysed using the 279 
following equation: Y=Ymin + (Ymax-Ymin)/(1+10((LogEC50-X).nH)), where X is the concentration of EFX, 280 
Ymin and Ymax are the minimum and highest responses, and nH is the Hill coefficient. 281 
2.11 Molecular model design 282 
The template chosen for homology modelling was the recently solved structure of a GABAAR 283 
(pdb code 4COF). The sequences of the human α2, β3 and γ2S GABAAR subunits were aligned with 284 
those of the template (β3) using T-Coffee software [41]. The model was then prepared by homology 285 
modeling using Modeler version 9.5 software [42] with default settings. One hundred models were 286 
prepared, and the best model, according to the Discrete Optimized Protein Energy function (DOPE), 287 
was selected. Side chains in the models were improved with Scwrl4 [43]. The whole model was then 288 
improved with CHARMM [44,45]. Disulfide bridges formed between neighbouring cysteines both in 289 
the ‘Cys-loop’ and between the M1 and M3 transmembrane helices in α and γ subunits, as recently 290 
proposed [45]. The model was then subjected to minimization with decreasing harmonic potential. 291 
2.12 Docking 292 
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The docking had been performed with AutoDock Vina [46]. The ligands and proteins were 293 
prepared with prepare_ligand4.py and prepare_receptor4.py scripts, respectively. The side chains of 294 
amino-acids in the binding site were made flexible (a3: Ser257 Ser258 and β3 Gln66, Tyr87, Gln89, 295 
Tyr91). Each ligand was docked 100 times in a large cube of 30 Å in each dimension. Fig. 7 was 296 
prepared with PyMOL (DeLano W.L. (2010) The PyMOL Molecular Graphics System, version 1.6, 297 
Schrodinger, LLC, New York). 298 
2.13 Data analysis and statistics 299 
Data are presented as the mean ± SEM. Behavioral data were analysed by one-way ANOVA 300 
followed by Dunnett’s post-hoc test for comparison with the vehicle group. In cases in which the two 301 
conditions (normality of the data and equality of variances) were not fulfilled, the non-parametric 302 
Kruskal-Wallis procedure was used, followed by the post-hoc Dunn’s test to evaluate the statistical 303 
significance between the vehicle and treated groups. All test analyses were carried out by observers 304 
who were blinded to the experimental procedures. Sample sizes (number of animals in the behavioral 305 
studies) were not predetermined by a statistical method. Each behavioral experiment group included 306 
at least 10 animals and this sample size needed to detect significant effects was based on experience 307 
from previous studies. Significance tests between groups in the electrophysiological studies were 308 
performed using variance analysis (one-way ANOVA) followed by Tukey’s post-hoc test for 309 
comparison of all groups or the non-parametric Mann and Whitney test when appropriate. Concerning 310 
the electrophysiological experiments, we compiled data from different batches of oocytes and we 311 
excluded data, in case of potential drift (> 0.6 mV) after pulling out the electrodes from the oocytes 312 
and when current amplitudes were <10 nA or > 2 µA. GraphPad Prism 7.02 (GraphPad Software, San 313 
Diego, USA) was used for all graphs and statistical analyses. Differences with p<0.05 were 314 
considered significant (* for p<0.05, ** for p<0.01, *** for p<0.001, **** for p<0.0001). 315 
316 
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3. Results 317 
3.1 Anxiolytic effects of EFX 318 
Previous studies have shown that EFX exhibits anxiolytic effects using conventional 319 
behavioral tests such as elevated plus maze and dark-light box tests [33,47]. Here, we evaluated the 320 
effect of EFX on stress and anxiety-related behaviors (stress-induced hyperthermia and novel object 321 
exploration) to determine and confirm its anxiolytic doses in comparison with BZP. In non-treated 322 
animals, handling stress resulted in a rise in body temperature close to 1°C (Fig. 2A to D). BZP 323 
significantly lowered body temperature in animals at 1 mg/kg dose, before handling (T0) revealing 324 
hypothermia (H(3)=11.343, p=0.010, then p<0.05, Dunn’s test) (Fig. 2A). BZP dose-dependently 325 
prevented stress-induced hyperthermia (F3,41=18.290, p<0.001) (Fig. 2B). Compared to the vehicle-326 
treated animals, BZP was effective at doses of 0.5 and 1 mg/kg (p<0.05, Dunnett’s test). EFX also 327 
induced changes in body temperature but without hypothermia at the highest dose (50 mg/kg) 328 
compared with control animals (F3,41 =2.269, p=0.095) (Fig. 2C). As observed for BZP, the 329 
temperature increase was dose-dependently prevented by EFX (H(3)=20.072, p<0.001) with a 330 
significant effect at 25 and 50 mg/kg dose (p<0.05, Dunn’s test) (Fig. 2D). The anxiolytic effects of 331 
BZP and EFX were also assessed by evaluating the behavioral approach in the presence of an 332 
unfamiliar object. The duration of contact with a novel object was significantly decreased in animals 333 
treated with BZP (H(3)=15.304, p=0.002) from the dose of 1 mg/kg (p<0.05, Dunn’s test) (Fig. 2E). 334 
The same was observed with EFX (H(3)=17.536, p<0.001), with a significant effect observed at doses 335 
of 25 and 50 mg/kg compared with the control animals (p<0.05, Dunn’s test) (Fig. 2F). In conclusion, 336 
these two different behavioral tests led to similar anxiolytic doses of EFX (25-50 mg/kg, IP).  337 
 338 
 339 
 340 
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 360 
 361 
Fig. 2. Comparison of the effects of EFX and BZP on anxiety-related behaviors in mice. (A-D) The graphs show the 362 
evolution of the mean rectal temperature (± SEM) at T0 and T0+10 min after treatment with vehicle (dose 0) or BZP (A) 363 
or EFX (C) through IP route, 60 min before the first temperature measurement at T0. Histograms represent the mean (± 364 
SEM) of the difference of the rectal temperature measured at T0 and T+10 min in the same mouse after treatment with 365 
vehicle or BZP (B) or EFX (D) at the indicated doses. *p<0.05 compared with the vehicle group (Dunn test). (E,F) 366 
Histograms illustrate the mean time (± SEM) of contact with an unfamiliar object after IP administration of BZP (E) or 367 
EFX (F). *p<0.05 compared with the respective vehicle groups (dose 0). (see “data analysis and statistics” in the Material 368 
and Methods section). Animal numbers are indicated inside the bars. 369 
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3.2 Motor performance assessment 370 
We then compared the impact of EFX and BZP on locomotion performance and motor 371 
coordination (Fig. 3). As illustrated in Fig. 3, BZP (IP route) decreased spontaneous locomotor 372 
activity (H(3)=8.229, p=0.042). These effects were statistically significant for the 1 mg/kg dose 373 
(p<0.05; Dunn’s test) (Fig. 3A). EFX (IP route) decreased spontaneous locomotor activity with a 374 
significant difference at 100 mg/kg (H(4)=9.633, p=0.047) compared to control animals (p<0.05, 375 
Dunn’s test) (Fig. 3B). BZP reduced the time on the rotarod (H(3)=9.167, p=0.027), with a significant 376 
effect at the 1 mg/kg dose (p<0.05, Dunn’s test) (Fig. 3C). EFX was devoid of any effect up to the 377 
100 mg/kg dose and affected motor coordination at the 150 mg/kg dose compared with control 378 
animals (H(5)=19.006, p=0.002 then p<0.05, Dunn’s test) (Fig. 3D). In conclusion, BZP triggers 379 
motor impairments at anxiolytic doses (1 mg/kg, IP), while EFX exhibits no locomotor effects at 380 
efficient anxiolytic doses (25 to 50 mg/kg, IP). 381 
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382 
Fig. 3. Comparison of BZP and EFX on locomotor activity and motor coordination. (A, B) Spontaneous locomotor 383 
activities were assayed in the actimeter test in mice after IP injections of BZP (A) or EFX (B). The bars represent the 384 
means ± SEM of the number of infrared beam interruptions over15 min. (C,D) Histograms illustrate the time on the rod 385 
(mean ± SEM) after injection of BZP (C) or EFX (D). Animal numbers are indicated inside the bars. *p <0.05 compared 386 
with the respective vehicle groups (see “data analysis and statistics” in the Material and Methods section).  387 
3.3 EFX effects on GABA currents depends on α subunit isoforms 388 
Because the distribution of GABAAR α subunits within the CNS is heterogeneous and 389 
contributes to their receptor functions, we next investigated the involvement of α subunits in the EFX 390 
mode of action using electrophysiology. To achieve this goal, we compared the effects of EFX (2 to 391 
100 µM) on GABA-induced currents elicited by α1GABAARs, α2GABAARs, α3GABAARs, 392 
α4GABAARs, α5GABAARs or α6GABAARs, containing β3 together with γ2S or d, when appropriate. 393 
We first challenged EFX effects on GABA-currents elicited by synaptic α1β3γ2S, α2β3γ2S 394 
and α3β3γ2S GABAARs expressed in Xenopus oocytes (Fig. 4). We observed that EFX displays both 395 
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agonist and potentiating effects as previously described [24]. The agonist effects of EFX were 396 
revealed by its perfusion before co-application with GABA at EC10 (Table S2). EFX exhibits almost 397 
no agonist effects on α1β3γ2S GABAARs (12.4 ± 5.8 and 23.7 ± 10.4 % of GABA EC10 at 50 and 100 398 
µM EFX, respectively) (Fig. 4A). In contrast, comparable agonist effects were observed with 399 
α2β3γ2S GABAARs (171 ± 24.9 % of GABA EC10, at 100 µM EFX, Fig. 4B) and α3β3γ2S GABAARs 400 
(153.6 ± 27.3% of GABA EC10, at 100 µM EFX, Fig. 4C). In comparison with GABA, EFX exerted 401 
weaker agonist effects (~100 fold less efficient). For these three receptors, EFX potentiation of GABA 402 
EC10-evoked currents was dose-dependent, reaching a plateau at 50 µM (Fig. 4). At this concentration, 403 
EFX induced a potentiation of GABA EC10-evoked currents by 68.9 ± 11.6%, 160.3 ± 40.2% and 404 
410.7 ± 20.2% of α1β3γ2S, α2β3γ2S and α3β3γ2S, respectively. The potentiating effects induced 405 
by EFX from 2 to 100 µM, was ~2.4-6.0-fold stronger (p<0.05) with α3β3γ2S than with α1β3γ2S 406 
and α2β3γ2S GABAARs. Taking in account both agonist and potentiating effects, α1β3γ2S GABAARs 407 
are found much less sensitive to EFX than α2β3γ2S and α3β3γ2S GABAARs. 408 
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Fig. 4. Effects of EFX on GABA-activated currents mediated by three synaptic GABAARs (a1β3γ2S, a2β3γ2S and 409 
a3β3γ2S). EFX effects were investigated by TEVC in Xenopus oocytes expressing a1β3γ2S (A), a2β3γ2S (B) and 410 
a3β3γ2S GABAARs (C). (A-C) Increasing concentrations of EFX (2, 20, 50 and 100 µM) were applied 2 min before co-411 
application of GABA at EC10 (inbox). The amplitudes of EFX-evoked currents (● ) were normalized to the amplitude of 412 
control currents (n) obtained with GABA alone at EC10. The potentiation effects of EFX was determined as the percentage 413 
increase of EC10-GABA current amplitudes (● ). Left panel, GABA EC10-induced representative currents are illustrated, 414 
showing the partial agonist and positive modulatory effects of EFX. Right panel, data points (mean ± SEM of 6-11 oocytes 415 
from at least two different animals) were fitted by non-linear regression to the Hill equation with variable slope using 416 
GraphPad Prism 7. Statistical analyses were performed using one-way ANOVA tests followed by Tukey’s post-hoc 417 
correction (comparison with data obtained at 2 µM, *p<0.05, **p <0.01; ***p <0.001; ****p <0.0001, ns: not significant). 418 
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Based on pharmacokinetic data [30], we estimated that 20 µM matches the concentration of 419 
free EFX in the mouse brain after injection of anxiolytic doses (25-50 mg/kg, Fig. 2). Thus, we 420 
compared agonist and potentiating effects of 20 µM EFX on α(1-3) β3γ2S GABAARs (Fig. 5A and 421 
B). EFX (20 µM) acts as a partial agonist on α2GABAARs and α3GABAARs, while these agonist 422 
effects are not significant on α1GABAARs (Fig. 5A). As for the potentiating effects, α3GABAARs 423 
were much more sensitive to EFX (245.6 ± 41.8%) than α1 (50.1 ± 12.5%) and α2 (101.7 ± 12.2% 424 
increase) -containing GABAARs (Fig. 5B). In the synaptic cleft the GABA concentration rapidly rises 425 
up to the millimolar range [48], we thus compared the GABA concentration-response relationships 426 
in the presence and absence of 20 µM EFX at α1GABAARs, α2GABAARs and α3GABAARs (Fig. 5C, 427 
Table 1). EFX induced a decrease of GABA EC50 with α1GABAARs and α2GABAARs in a similar 428 
extent (~4-fold). In contrast, the GABA potency on α3GABAARs was increased by 20.6 (Fig. 5C). 429 
Taken together, our electrophysiological data show that, EFX behaves as a selective PAM of 430 
α3GABAARs at concentration equivalent to anxiolytic doses.  431 
  432 
Page	22	of	37	
	
Fig. 5. Pharmacological profile of EFX over a(1-3)b3g2S GABAARs. Comparison of EFX effects at 20 µM corresponding 433 
to anxiolytic doses. Detailed analysis of agonist (A) and potentiating (B) effects of 20 µM EFX on a1b3g2S, a2b3g2S 434 
and a3b3g2S GABAARs. One-way ANOVA followed by Tukey post-hoc test was used for the analysis ((*p<0.05, **p 435 
<0.01; ***p <0.001; ****p <0.0001). The number of recorded oocytes is indicated above or inside the bars. (C) 436 
Concentration-response curves of GABA-evoked currents in the absence (open circles) and presence (close circles) of 20 437 
µM EFX. Statistical analyses were performed using a non-parametric Mann & Whitney unpaired t-test. All data are 438 
expressed as the mean ± SEM (n ≥ 6). 439 
Table 1 440 
Parameters of the GABA concentration-response relationship at a1b3g2S, a2b3g2S and a3b3g2S 441 
GABAARs modulated by 20 µM EFX.  442 
 control + 20 µM EFX 
GABAAR subtype EC50 (µM) nH EC50 (µM) nH 
a1b3g2S 9.99 ± 0.96 1.06 ± 0.09 2.37 ± 0.11 1.41 ± 0.08  
a2b3g2S 1.31 ± 0.12 1.69 ± 0.28 0.32 ± 0.03 1.14 ± 0.01 
a3b3g2S 10.89 ± 0.61 1.34 ± 0.09 0.53 ± 0.08 1.05 ± 0.15 
The concentration-response relationships were analyzed using the Hill-Langmuir equation with variable slope. nH : Hill 443 
slope. The data are mean ± SEM of at least two independent experiments.  444 
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Next, we tested EFX on synaptic α4β3γ2S GABAARs and extrasynaptic α4β3d GABAARs. In 445 
both cases, EFX did not exhibit any agonist effects nor significantly potentiate GABA-induced 446 
currents, even at high concentrations (Fig. 6A,B). Conversely, DZP at 2 µM enhanced GABA currents 447 
elicited by α4β3γ2S GABAARs, as previously reported [49], but it did not affect α4β3d GABAARs 448 
(Fig. 6A,B). The extrasynaptic α5β3γ2S GABAARs appeared to be also insensitive to EFX at low 449 
concentrations (2 and 20 µM), and weakly sensitive to EFX at 50 µM (54.26 ± 29.19%) (Fig. 6C and 450 
D). At 100 µM, EFX effects were significantly increased but did not reach a plateau (212.0 ± 31.97%). 451 
The α6 subunit was expressed with γ or d in accordance with the native GABAAR composition in the 452 
cerebellum [50]. Similar agonist effects were observed with α6β3γ2S GABAARs (76.9 ± 20.3% of 453 
GABA EC10, at 100 µM EFX,) and α6β3δ GABAARs (46.8 % of GABA EC10, at 100 µM EFX) (p=0.23, 454 
Mann and Whitney test) (Fig. 6E,F) as seen with α2GABAARs and α3GABAARs (Fig. 4B,C). 455 
Moreover, the PAM effects of EFX revealed equal sensitivities of synaptic α6β3γ2SGABAARs and 456 
extrasynaptic α6β3δ GABAARs. EFX-potentiation of GABA-evoked currents reached a plateau at 50 457 
µM EFX (170.5 ± 48.4% increase for α6β3γ2S GABAARs and 143.6 ± 22.3% for α6β3δ GABAARs, 458 
p>0.99, Mann and Whitney test) in accordance with a specific concentration-dependent mode of 459 
action (Fig. 6E and F).  460 
 461 
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Fig. 6. Effects of EFX on GABA EC10-activated currents mediated by synaptic (a4β3γ2S and a6 β3γ2S) and extrasynaptic 462 
(a4β3δ, a5β3γ2S and a6β3δ) GABAARs. (A) Superimposed current traces evoked by GABA EC10 in a representative cell 463 
expressing a4β3γ2S or a4β3δ GABAARs in the absence (black traces) or presence of DZP (2 µM) or EFX. (B) Graphs 464 
illustrating the mean (± SEM) EFX potentiation of GABA EC10-activated currents mediated by synaptic and extrasynaptic 465 
a4GABAARs. (C) Current traces evoked by GABA EC10 in a representative oocyte expressing extrasynaptic a5β3γ2S 466 
GABAARs in the absence (black trace) or presence of EFX (2 to 100 µM). (D) Graphs showing the mean (± SEM) EFX 467 
potentiation of GABA EC10-evoked currents. Statistical analyses were performed by one-way ANOVA followed by Tukey 468 
post-hoc test (*p<0.05, **p <0.01; ***p <0.001; ****p <0.0001, ns: not significant). (E) Current traces evoked by GABA 469 
EC10 with synaptic a6β3γ2S and extrasynaptic a6β3δ GABAARs in the absence (black traces) or presence of increasing 470 
concentrations of EFX (2 to 100 µM). (F) Graphs showing the mean (± SEM) EFX potentiation of GABA EC10-activated 471 
currents mediated by a6β3γ2S and a6β3δ GABAARs. Statistical analyses were performed using a non-parametric Mann 472 
& Whitney unpaired t-test (* p<0.05; ns: not significant). 473 
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In conclusion, taking into account both agonist and potentiating EFX effects, GABAARs can 474 
be ranked in three categories: i) resistant (α4GABAARs and α5GABAARs), ii) moderately sensitive 475 
(α1GABAARs, α2GABAARs and α6GABAARs) and iii) highly sensitive (α3GABAARs) to EFX. 476 
3.7 Modelling of EFX-α3β3γ2s GABAAR interaction 477 
To gain further insight into the mechanism of action of EFX, we generated a homology model 478 
of α3β3γ2s GABAAR (Fig. 7A) to predict how EFX binds to its receptor site. The resulting computed 479 
docking model was consistent with an EFX binding site located between α and β subunits in the 480 
extracellular domain (Fig. 7B and C). The pocket found at the interface between α3 and β3 subunits, 481 
homologous to the GABA binding sites, was large enough to accommodate EFX. Among the putative 482 
binding modes, one was found in which EFX bound in the proximity of five amino acid residues of 483 
the β3 subunit: N66, Y87, Q89, Y91 and R194 (Fig. 7D). In α3 subunit, we identified two amino acid 484 
residues (S257, S258) that may be involved in the EFX-GABAAR interaction. Two residues of β3, 485 
N66 and R194, are conserved in β2 and β3 and are different in β1 subunits (R66 and N194). This pair 486 
of amino acids might therefore control the binding mode of EFX as variations at these residues might 487 
explain the subunit selectivity. 488 
 489 
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Fig. 7. Binding modes of EFX obtained by docking on the mouse α3β3γ2S GABAAR. (A) Model of the receptor viewed 490 
from the membrane plane. The protein is shown in cartoon representation with a different color code for each polypeptide. 491 
The position of the membrane is represented by a sphere positioned at the level of lipid head groups as determined by the 492 
Orientations of Proteins in Membranes database [51]. (B-D) Binding mode of EFX by docking on the mouse 493 
α3β3γ2SGABAAR model. EFX (CPK representation) interacts with a pocket localized at the α3 (cyan) β3 (magenta) 494 
interface, homologous to GABA binding sites. The binding sites of BZD, GABA and EFX are indicated by arrows (B). 495 
Lateral view of the extracellular domain (C). Close-up showing the EFX-binding pocket (EFX appears in sticks) (D).  496 
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4. Discussion 497 
The current study shows that a single administration EFX (25-50 mg/kg) induced a robust 498 
anxiolytic behavior in mice subjected to stress-induced hyperthermia and novel object exploration 499 
tests. In the same range of doses, and unlike classical BZDs, EFX did not evoke any secondary effects 500 
in the spontaneous locomotor activity and rotarod performance. Pharmacokinetic data in Balb/cByJ 501 
mice treated with anxiolytic doses indicated that EFX brain content reaches concentration range from 502 
16 to 31 µM [30]. In addition, EFX exhibits lipophilic properties with an estimated partition 503 
coefficient (log P) of 2 and a brain/ plasma ratio range of 2.2-2.9 [52]. Based on different reports in 504 
the literature, it is reasonable to assume that an equilibrium between the total and free fractions which 505 
depends on physicochemical properties of the compound occurs in the brain tissue [53-55] and, as a 506 
result this could support the relevance of the effective concentrations in the present 507 
electrophysiological studies. In this context, we demonstrated that the a subunit plays an important 508 
role in EFX-induced positive effects on GABAARs. EFX favours GABA potency over GABAARs with 509 
the following rank order: α3b3g2S > α2b3g2S > α6b3g2S and no or weak effects on α1b3g2S, 510 
α4b3g2S and α5b3g2S.  511 
4.1 EFX displays anxiolytic properties with weak side effects 512 
Our findings confirm the anxiolytic properties of EFX at similar doses to those previously 513 
used in other anxiety mouse models [30]. In comparison, EFX displays approximately 50-fold less 514 
potent anxiolytic effects than BZP and DZP [8,9]. However, both BZP and DZP strongly alter 515 
locomotor performance and awakening at anxiolytic doses, while EFX does not. It is noteworthy that 516 
pharmacokinetic factors involving, for example, active metabolites or differences in the extent of 517 
metabolism could explain the differences in the effective doses of EFX and BZP. We reasoned that 518 
BZDs, which have a high potency (submicromolar) for enhancing GABA-evoked currents, will 519 
produce effects at a lower concentration than EFX which has a lower potency (micromolar) for 520 
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GABAARs. Interestingly, EFX exhibits higher efficacy for α2GABAARs and α3GABAARs, known to 521 
mediate anxiolytic effects (up to 171% and 410% for α2GABAARs and α3GABAARs, respectively) 522 
than DZP (108% and 160% for α2GABAARs and α3GABAARs, respectively) [56]. 523 
Compelling evidence indicates that the anxiolytic effects of BZP cannot be dissociated from 524 
its sedative and myorelaxant effects, while the therapeutic margin is wider with EFX. In addition, 525 
previous results have shown that EFX is devoid of amnesic effects at anxiolytic doses (50 mg/kg, IP 526 
route) in the rat [57]. On the other hand, BZP and DZP display amnesic activity at doses producing 527 
anxiolytic effects (from 0.25mg/kg, IP) in the mouse [58]. As observed in rodents, patients treated 528 
with EFX for adjustment disorders with anxiety do not exhibit adverse effects, such as the memory 529 
and vigilance disturbances [19,59,60]. This is perfectly in line with our electrophysiological data 530 
showing the absence of effects of EFX on a4GABAARs and a5GABAARs, known to be involved in 531 
cognitive functions [4].  532 
We cannot rule out the possibility that EFX anxiolytic properties rely on both direct and 533 
indirect GABAAR stimulation mechanisms. Since EFX has been shown to stimulate the synthesis of 534 
neurosteroids, such as allopregnenolone, which directly boosts GABAAR activity [27,43,61], this may 535 
account for its anxiolytic effects. Neurosteroids equally enhance GABA-evoked currents mediated 536 
by a1GABAARs, a3GABAARs and a6GABAARs, while they have little effects on α2GABAARs, 537 
α4GABAARs and α5GABAARs [58,62], suggesting that EFX should induce both sedation and 538 
anxiolysis. However, because EFX did not induce sedation at anxiolytic doses, this minors the 539 
involvement of neurosteroids in the EFX mode of action. We hypothesize that EFX may exert its 540 
anxiolytic effect through a direct enhancement of the activity of GABAARs. To date, there is no 541 
experimental data on EFX modulation of GABAARs to conclude a plausible mode of action. However, 542 
using recombinant murine GABAARs expressed in Xenopus oocytes, it has been shown that both 543 
efficacy and potency of GABA are enhanced by EFX [24]. The effect of EFX might be explained by 544 
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either mechanism, i.e. an increased frequency of the open state of GABAARs and/or an increase of the 545 
duration of burst openings.  546 
Further studies using a chronic treatment are warranted to support the specificity of EFX 547 
compared to BZDs in the development of tolerance complex phenomenom involving in part selective 548 
alterations in GABAAR receptor subunit expression [63]. 549 
4.2 The EFX mode of action depends on the GABAAR α subunits 550 
Our electrophysiological data demonstrate that EFX behaves both as a partial agonist and a 551 
PAM of GABAARs. In fact, EFX strongly potentiates GABA-evoked currents mediated by 552 
α2GABAARs, α3GABAARs and/or α6GABAARs, with major effects on α3GABAARs in comparison to 553 
any other GABAARs. This was also highlighted by a larger enhancement of the GABA potency on 554 
α3GABAARs, than on α1GABAARs and α2GABAARs. However, the involvement of α3GABAARs in 555 
anxiolysis is still a matter of debate. As mentioned above, there is still a controversy concerning the 556 
implication of α2GABAARs, α3GABAARs and α5GABAARs in the control of anxiety-related 557 
behaviors [14,15,17,64]. Other non-BZD compounds such as TPA023, AZD6280 and AZD7325, 558 
have been shown to exert anxiolysis without sedative side effects in rodents and/or humans by 559 
preferentially enhancing α2GABAARs and a3GABAARs over the other GABAAR subtypes [64,65]. 560 
However, these three compounds bind to the BZD site, while EFX does not [23]. In addition, another 561 
non-BZD compound, TP003 was first reported as a selective PAM of α3GABAAR, and initially 562 
considered to exhibit anxiolytic properties through this receptor [14,66]. However, two recent studies 563 
have revealed that this drug is not selective to α3GABAAR, but equally modulates GABA-evoked 564 
currents mediated by α5GABAAR and also moderately potentiates α1GABAARs and α2GABAAR 565 
[65,67]. TP003 was indeed shown to counteract anxiety behaviors in both rodents and squirrel 566 
monkeys and thus highlights the medical use of α3GABAAR-selective molecules as efficient 567 
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anxiolytics with no sedative secondary effects [14,66]. Therefore, we believe that the anxiolytic-like 568 
effects of EFX in mice are related to the modulation of α2GABAARs and α3GABAARs. 569 
4.3 The EFX binding site 570 
Our objective was to challenge the possible influence of the α subunit for at least three reasons. 571 
First, β2 homopentamers are less sensitive to EFX than β3 homopentamers. However, when they are 572 
combined with α1 or α2 subunits, the resulting binary GABAARs display a different pharmacological 573 
profile: α1β2-3 and α2β2-3 GABAARs are equally potentiated, indicating that α1 and α2 subunits 574 
modulate EFX potentiation [24]. Second, α1 and α2 subunits share a high amino acid sequence 575 
identity, while α4-6 are structurally more distant [68] and thus could potentially have distinct 576 
pharmacological influences. Here, we bring compelling evidences demonstrating that stimulating 577 
effects of EFX are much stronger on α3β3γ2S than on α2β3γ2S, α6β3γ2S and α1β3γ2S GABAARs, 578 
while α4β3γ2S and α5β3γ2S are almost insensitive. Altogether, our findings indicate a strong 579 
regulatory effect of the α subunit on EFX mode of action. 580 
We also examined the involvement of γ2S and d subunits in the mode of action of EFX and 581 
we observed that α4β3γ2S and α4β3d on one hand, α6β3γ2S and α6β3d GABAARs on the other hand, 582 
are equally sensitive to EFX. This reinforces the idea that, unlike BZDs [7], the third subunit is not 583 
involved in the EFX-GABAAR interaction.  584 
Consecutively, we hypothesized that EFX site is likely located between the α and β subunits. 585 
Our 3D docking simulation suggests that EFX binds in a pocket at the α/β subunit interface 586 
homologous to the GABA binding pocket recently described [69], highlighting putative amino acid 587 
residues involved in EFX binding. Interestingly, among them, two residues of β3, N66 and R194, are 588 
conserved in β2 and β3 and differ in the β1 subunits (R66 and N194). This pair of amino acids may 589 
belong to the binding site of EFX and summarise its subunit selectivity. Site-directed mutagenesis 590 
experiments are required to validate this hypothesis and to define the residues underlying the EFX 591 
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selectivity towards α3GABAARs. These experiments will allow us to construct genetic models in 592 
which specific α(1-6)GABAARs subtypes will be rendered insensitive to EFX to directly correlate 593 
specific α2GABAARs or α3GABAARs to its anxiolytic effects or test whether α3GABAAR functions 594 
are involved in the regulation of anxiety. 595 
5. Conclusions 596 
In conclusion, this study provides new information about the mode of action of EFX, a non-597 
BZD anxiolytic compound, showing that it potentiates GABA transmission, mainly through the 598 
interaction with α2GABAARs and α3GABAARs and likely their associated functions. Modelling 599 
simulation indicates that EFX could interact with a pocket localized at the α/β subunits 600 
interface,homologous to the GABA binding site. To the best of our knowledge, EFX belongs to the 601 
group of non-BZD molecules which act at a site distinct from the classical BZDs site and exert 602 
positive effects on anxiety without secondary effects. EFX may therefore serve as a molecular 603 
template for the design of novel anxiolytics with similar mechanisms of action and higher potency. 604 
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